Exploring New Treatment Options for Alzheimer's Disease

Published date: |
Estimated read time: |
Authored by:
  • AdventHealth Research Institute
Topics:
Care

“The inflammatory changes that lead to neurodegeneration, including Alzheimer’s disease, are critical and unexplored and could provide a new mechanism for achieving meaningful clinical benefit. We need to look beyond the amyloid targeting pathway and identify additional interventions in patients for whom other treatments have not been appropriate or effective. If we can show that troculeucel can improve cognitive function in patients who continue to progress on amyloid targeting therapy, that would be a huge step forward, providing new hope to the millions of people suffering from Alzheimer’s disease.” -- Anita Fletcher, MD, Director of Neuroscience Clinical Research, AdventHealth Neuroscience Institute

On July 10, 2025, Dr. Fletcher worked with NKGen Biotech to administer the first dose of troculeucel (SNK01), an investigative natural killer (NK) cell therapy, to a patient with Alzheimer’s disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab, an amyloid targeting therapy. The treatment was administered under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA). Click below to read more.

Read More

Recent News

News

Conform Trial: Major Milestone Achieved

On August 8, 2025, our team successfully completed the very first implant day for the Conform Clinical Trial, enrolling and treating our first three patients with the Conformal CLAAS System for Left...

Read Article